Class ActionDid Manufacturer of Low-T Drug Disclose Risks?
Posted in Class Action on May 16, 2014
Five individuals have filed a lawsuit against the manufacturer of Low-T testosterone therapy drug AndroGel. The suit has alleged that AbbVie and Abbott Laboratories concealed facts about AndroGel and serious side-effects associated with the drug. According to the suit, the manufacturer failed to adequately research the risks of stroke or heart attack from testosterone therapy,… read more…Actos Litigation Continues
Posted in Class Action on May 12, 2014
Litigation involving the drug Actos (Pioglitazone) is continuing in the class actions posture following a verdict in a bellweather case in excess of $9 billion dollars. The manufacturer of Actos,Takeda Pharmaceutical Co., made more than $16 billion before Actos went generic in 2012. While internal records show that Takeda knew about a link between Actos… read more…